Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2021

  1. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

    Radiology, Vol. 299, Núm. 1, pp. 109-119

  2. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

    European Journal of Cancer, Vol. 155, pp. 168-178

2020

  1. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria

    Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855

  2. Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial

    Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317

2019

  1. Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials

    Expert Opinion on Investigational Drugs, Vol. 28, Núm. 5, pp. 463-471

2018

  1. Early evolutionary divergence between papillary and anaplastic thyroid cancers

    Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460

  2. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer

    Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629

  3. The safety of ramucirumab for the treatment of colorectal cancer

    Expert Opinion on Drug Safety, Vol. 17, Núm. 9, pp. 945-951